BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 15816500)

  • 1. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR; Tian J; Goltzman D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
    Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
    Wu-Wong JR; Melnick J
    Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D analogs: novel therapeutic agents for cardiovascular disease?
    Reinhart GA
    Curr Opin Investig Drugs; 2004 Sep; 5(9):947-51. PubMed ID: 15503649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells.
    Wu-Wong JR; Nakane M; Ma J
    Thromb Res; 2006; 118(6):709-14. PubMed ID: 16371233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D: an old prohormone with an emergent role in chronic kidney disease.
    Coen G
    J Nephrol; 2008; 21(3):313-23. PubMed ID: 18587719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D supplementation in CKD.
    Martin KJ; González EA
    Clin Nephrol; 2011 Apr; 75(4):286-93. PubMed ID: 21426882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins do not affect mineral metabolism in chronic kidney disease: a retrospective analysis.
    Ashman N; Banerjee A; Yaqoob MM
    Nephron Clin Pract; 2009; 111(4):c236-9. PubMed ID: 19287183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of vitamin D in vascular calcification in chronic kidney disease.
    Wolisi GO; Moe SM
    Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
    Dusilová Sulková S
    Vnitr Lek; 2012 Nov; 58(11):839-49. PubMed ID: 23256830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.